Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12644

    +

    P3.10-052 - Taxane monotherapy in advanced EGFR mutation positive lung cancer:<br /> A single institution experience (ID 3346)

    09:30 - 09:30  |  Author(s): R. Martins
    • Abstract

    Background
    Lung cancers harboring epidermal growth factor receptor (EGFR) activating mutations are sensitive to EGFR tyrosine kinase inhibitor (TKI) therapy with tumor response rates of 70-80%. However, patients eventually develop resistance requiring the use of cytotoxic chemotherapy. Currently, the optimal chemotherapeutic agent in this molecular subtype is unknown. We have observed at our institution that EGFR mutation positive lung cancers are sensitive to subsequent taxane therapy. Here we present a single institutional experience of EGFR mutation positive lung cancer patients who have been treated with a taxane monotherapy after a prior TKI therapy.

    Methods
    This retrospective case series includes patients with advanced lung cancer with a documented EGFR mutation who have been treated with an EGFR TKI and who received subsequent taxane monotherapy between November 2006 and April 2013. The response rate was analyzed using RECIST 1.1. The overall disease control rate was evaluated at 8 weeks. Only the patients who received treatment for at least 4 weeks and who were evaluable for response were included in the analysis.

    Results
    Among the 19 patients identified, 17 patients were included in the analysis. Ten (59%) patients were found to have exon 19 deletion and five (29%) had exon 21 L858R point mutation. The median age of patients was 68 (range 46 – 78) and 65% were women. Sixteen (94%) patients received weekly paclitaxel 90mg/m2 d and one patient (6%) received docetaxel 60mg/m2 every 3 weeks. Patients had received a median of 3 previous lines of therapy (range 1-5) which included prior TKI therapy. Median duration of treatment was 4.0 months (range 1.0 – 9.6). Partial responses (PR) were observed in 4 (24%) patients with a median tumor reduction of 59.8% (range 37.7 – 76.4%) and the median duration of response was 6.9 months (range 6.5 - 7.0). Stable disease (SD) at 8 weeks was observed in 10 (59%) patients with a median tumor reduction of 18.7%. Median duration of stable disease was 4.0 months (range 3.3 - 9.6). The overall disease control rate (PR + SD) at 8 weeks was 82% (14/17). Figure 1

    Conclusion
    Patients with EGFR mutation positive lung cancers exhibit excellent disease control with taxane monotherapy in this case series, even in heavily pretreated patients. The role of taxane monotherapy in this patient population is currently being evaluated in a prospective phase II trial at our institution. Further investigation of the biological mechanism of this finding is warranted.